Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Nat Commun. 2020 Mar 19;11(1):1459. doi: 10.1038/s41467-020-15315-8.
Nat Commun. 2020.
PMID: 32193378
Free PMC article.
Clinical Trial.